SARS-CoV-2 Modulation of HIV Latency Reversal in a Myeloid Cell Line: Direct and Bystander Effects
Viruses · 2024
DOI: 10.3390/v16081310 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Patricio Jarmoluk und 7 weiteren Autor:innen. Beteiligte Einrichtung: Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET), Instituto de Investigaciones Biomédicas en Retrovirus y Sida (INBIRS), Labo…. Hauptthemen laut MEDLINE: Virus Latency, SARS-CoV-2, HIV-1, COVID-19. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación, Governo Italiano, Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT).
Abstract (Originalsprache)
Coronavirus disease 2019 (COVID-19) might impact disease progression in people living with HIV (PLWH), including those on effective combination antiretroviral therapy (cART). These individuals often experience chronic conditions characterized by proviral latency or low-level viral replication in CD4+ memory T cells and tissue macrophages. Pro-inflammatory cytokines, such as TNF-α, IL-1β, IL-6, and IFN-γ, can reactivate provirus expression in both primary cells and cell lines. These cytokines are often elevated in individuals infected with SARS-CoV-2, the virus causing COVID-19. However, it is still unknown whether SARS-CoV-2 can modulate HIV reactivation in infected cells. Here, we report that exposure of the chronically HIV-1-infected myeloid cell line U1 to two different SARS-CoV-2 viral isolates (ancestral and BA.5) reversed its latent state after 24 h. We also observed that SARS-CoV-2 exposure of human primary monocyte-derived macrophages (MDM) initially drove their polarization towards an M1 phenotype, which shifted towards M2 over time. This effect was associated with soluble factors released during the initial M1 polarization phase that reactivated HIV production in U1 cells, like MDM stimulated with the TLR agonist resiquimod. Our study suggests that SARS-CoV-2-induced systemic inflammation and interaction with macrophages could influence proviral HIV-1 latency in myeloid cells in PLWH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET), Instituto de Investigaciones Biomédicas en Retrovirus y Sida (INBIRS), Laboratorio de Inmunopatología Viral, Universidad de Buenos Aires (UBA), B…
- Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
- School of Medicine, Vita-Salute San Raffaele University, 20132 Milan, Italy.
ORCID-Profile: Cintia Cevallos, Rosa Nicole Freiberger, Cynthia Alicia López, Guido Poli, M Victoria Delpino, Jorge Quarleri
Förderung
- Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación
- Governo Italiano
- Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT)
- “Bando PRIN 2022” of the Italian Ministry of University and Research
Zitieren
APA
Jarmoluk, P., Sviercz, F. A., Cevallos, C., Freiberger, R. N., López, C. A., Poli, G., Delpino, M. V., & Quarleri, J. (2024). SARS-CoV-2 Modulation of HIV Latency Reversal in a Myeloid Cell Line: Direct and Bystander Effects. Viruses. https://doi.org/10.3390/v16081310
Vancouver
Jarmoluk P, Sviercz FA, Cevallos C, Freiberger RN, López CA, Poli G, et al. SARS-CoV-2 Modulation of HIV Latency Reversal in a Myeloid Cell Line: Direct and Bystander Effects. Viruses. 2024. doi:10.3390/v16081310
BibTeX
@article{Jarmoluk2024,
author = {Jarmoluk, Patricio and Sviercz, Franco Agustín and Cevallos, Cintia and Freiberger, Rosa Nicole and López, Cynthia Alicia and Poli, Guido and Delpino, M Victoria and Quarleri, Jorge},
title = {SARS-CoV-2 Modulation of HIV Latency Reversal in a Myeloid Cell Line: Direct and Bystander Effects},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16081310}
}
EUVIMED